{"url_path":"/sec/abbv/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1551152/0001551152-26-000017-index.html","accession_number":"0001551152-26-000017","cik":"0001551152","ticker":"ABBV","issuer_name":"AbbVie Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1551152/0001551152-26-000017-index.html","primary_entity_key":"0001551152","primary_entity_name":"AbbVie Inc."},"word_count":311,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\nExhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.\n\nExhibit No.Exhibit Description\n\n[10.1](abbv-20260331xex101.htm)\n\n[Form of](abbv-20260331xex101.htm)[AbbVie](abbv-20260331xex101.htm)[Inc. Performance-Vested Restricted Stock Unit Agreement*](abbv-20260331xex101.htm)\n\n[10.2](abbv-20260331xex102.htm)\n\n[Form of AbbVie Inc. Performance Share Award Agreement*](abbv-20260331xex102.htm)\n\n[10.3](abbv-20260331xex103.htm)\n\n[Form of AbbVie Inc. Non-Qualified Stock O](abbv-20260331xex103.htm)[ption](abbv-20260331xex103.htm)[Agreement.*](abbv-20260331xex103.htm)\n\n[31.1](abbv-20260331xex311.htm)\n\n[Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).](abbv-20260331xex311.htm)\n\n[31.2](abbv-20260331xex312.htm)\n\n[Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).](abbv-20260331xex312.htm)\n\n[32.1](abbv-20260331xex321.htm)\n\n[Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](abbv-20260331xex321.htm)\n\n[32.2](abbv-20260331xex322.htm)\n\n[Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](abbv-20260331xex322.htm)\n\n101\nThe following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 8, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity (Deficit); (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements.\n\n104Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101).\n\n_______________________________________________________________________________\n\n* Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.\n\n2026 Form 10-Q |\n\n33\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nABBVIE INC.\n\nBy:\n/s/ Scott T. Reents\n\nScott T. Reents\n\nExecutive Vice President,\n\nChief Financial Officer (Principal Financial Officer)\n\nDate: May 8, 2026\n\n2026 Form 10-Q |\n\n34"}